Sienna+MR Long-term Uptake

In a previous study in 2012/2013 patients were injected a superparamagnetic iron oxide for sentinel lymph node detection. In this follow up study we want to investigate how much of this tracer is still detectable.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Female

Sex eligibility

Female

Study type

Observational

Primary location

Kantonsspital Baden

Baden, Canton of Aargau, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

inclusion:

participation in previous study
informed consent
no contraindications for MRI scan

exclusion:

contraindications for MRI scan

Treatment and study plan

Native 1,5 Tesla breast MRI

Procedure

Primary outcomes

I) Analysis if the supraparamegnetic Tracer is still detectable

Time frame: 04/2017

Analysis by two expert radiologists

Secondary outcomes

Analysis to which degree of impairment of Imaging is detected

Time frame: 04/2017

Description as "no impairment", impairment, but Interpretation of Images possible", "impairment, Image Interpretation impossible"

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Kantonsspital Baden

Other

Registry information

Official study title

Feasibility of Breast MRI After Sentinel Procedure for Breast Cancer With Superparamagnetic Tracers

Important dates

Study start: 2016
Primary completion: 2017
Study completion: 2017
First posted: Aug 9, 2017
Registry last updated: Aug 9, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed